Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older

Show simple item record

dc.contributor.author Cunningham, Anthony L.
dc.contributor.author Heineman, Thomas C.
dc.contributor.author Lal, Himal
dc.contributor.author Godeaux, Olivier
dc.contributor.author Chlibek, Roman
dc.contributor.author Hwang, Shinn-Jang
dc.contributor.author McElhaney, Janet E.
dc.contributor.author Vesikari, Timo
dc.contributor.author Andrews, Charles
dc.contributor.author Choi, Won Suk
dc.contributor.author Esen, Meral
dc.contributor.author Ikematsu, Hideyuki
dc.contributor.author Choma, Martina Kovac
dc.contributor.author Pauksens, Karlis
dc.contributor.author Ravault, Stephanie
dc.contributor.author Salaun, Bruno
dc.contributor.author Schwarz, Tino F.
dc.contributor.author Smetana, Jan
dc.contributor.author Vanden Abeele, Carline
dc.contributor.author Van den Steen, Peter
dc.contributor.author Vastiau, Ilse
dc.contributor.author Weckx, Lily Yin [UNIFESP]
dc.contributor.author Levin, Myron J.
dc.date.accessioned 2018-07-26T12:18:34Z
dc.date.available 2018-07-26T12:18:34Z
dc.date.issued 2018
dc.identifier http://dx.doi.org/10.1093/infdis/jiy095
dc.identifier.citation Journal Of Infectious Diseases. Cary, v. 217, n. 11, p. 1750-1760, 2018.
dc.identifier.issn 0022-1899
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/45983
dc.description.abstract Background. The herpes zoster subunit vaccine (HZ/su), consisting of varicella-zoster virus glycoprotein E (gE) and AS01(B) Adjuvant System, was highly efficacious in preventing herpes zoster in the ZOE-50 and ZOE-70 trials. We present immunogenicity results from those trials. Methods. Participants (ZOE-50: >= 50 en
dc.description.abstract ZOE-70: >= 70 years of age) received 2 doses of HZ/su or placebo, 2 months apart. Serum anti-gE antibodies and CD4 T cells expressing >= 2 of 4 activation markers assessed (CD4(2+)) after stimulation with gE-peptides were measured in subcohorts for humoral (n = 3293) and cell-mediated (n = 466) immunogenicity. Results. After vaccination, 97.8% of HZ/su and 2.0% of placebo recipients showed a humoral response. Geometric mean anti-gE antibody concentrations increased 39.1-fold and 8.3-fold over baseline in HZ/su recipients at 1 and 36 months post-dose 2, respectively. A gE-specific CD4(2+) T-cell response was shown in 93.3% of HZ/su and 0% of placebo recipients. Median CD42+ T-cell frequencies increased 24.6-fold (1 month) and 7.9-fold (36 months) over baseline in HZ/su recipients and remained >= 5.6-fold above baseline in all age groups at 36 months. The proportion of CD4 T cells expressing all 4 activation markers increased over time in all age groups. Conclusions. Most HZ/su recipients developed robust immune responses persisting for 3 years following vaccination. en
dc.description.sponsorship GlaxoSmithKline Biologicals SA
dc.format.extent 1750-1760
dc.language.iso eng
dc.publisher Oxford Univ Press Inc
dc.rights Acesso aberto
dc.subject varicella-zoster virus en
dc.subject herpes zoster vaccine en
dc.subject gE subunit vaccine en
dc.subject adjuvant system en
dc.subject immunogenicity en
dc.title Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older en
dc.type Artigo
dc.description.affiliation Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia
dc.description.affiliation GSK, King Of Prussia, PA USA
dc.description.affiliation GSK, Wavre, Belgium
dc.description.affiliation Univ Def, Fac Mil Hlth Sci, Hradec Kralove, Czech Republic
dc.description.affiliation Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan
dc.description.affiliation Natl Yang Ming Univ, Sch Med, Taipei, Taiwan
dc.description.affiliation Hlth Sci North Res Inst, Sudbury, ON, Canada
dc.description.affiliation Univ Tampere, Vaccine Res Ctr, Tampere, Finland
dc.description.affiliation Diagnost Res Grp, San Antonio, TX USA
dc.description.affiliation Korea Univ, Coll Med, Dept Internal Med, Div Infect Dis, Seoul, South Korea|Univ Clin Tuebingen, Inst Trop Med, Tubingen, Germany
dc.description.affiliation Japan Phys Assoc, Chiyoda Ku, Tokyo, Japan|GSK, Rockville, MD USA
dc.description.affiliation Uppsala Univ Hosp, Dept Infect Dis, Uppsala, Sweden
dc.description.affiliation GSK, Rixensart, Belgium
dc.description.affiliation Standort Juliusspital, Klinikum Wurzburg Mitte, Cent Lab & Vaccinat Ctr, Wurzburg, Germany
dc.description.affiliation Univ Fed Sao Paulo, Sao Paulo, Brazil
dc.description.affiliation Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA
dc.description.affiliation Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA
dc.description.affiliation Genocea Biosci, Cambridge, MA USA
dc.description.affiliation Pfizer Inc, Collegeville, PA USA
dc.description.affiliation Janssen Vaccines & Prevent, Leiden, Netherlands
dc.description.affiliationUnifesp Univ Fed Sao Paulo, Sao Paulo, Brazil
dc.identifier.file WOS000434081100009.pdf
dc.identifier.doi 10.1093/infdis/jiy095
dc.description.source Web of Science
dc.identifier.wos WOS:000434081100009



File

Name: WOS000434081100009.pdf
Size: 3.041Mb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account